Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Investor Presentation (May 2026)
14 slides from Amplia Therapeutics's investor presentation, May 2026
Slide 1: Targeting pancreatic cancer and beyond
Targeting pancreatic cancer and beyond MAY 2026 ampliatx.com | @ampliatx ASX: ATX | OTCQB: INNMF 1
Slide 2: Disclaimer
01 Disclaimer This presentation (Presentation) contains summary information about Amplia Therapeutics Limited ACN Forward-looking statements are based on the Company’s good faith assumptions as to the financial 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 31 March
Slide 3: Pancreatic Cancer
02 Pancreatic Cancer rd $3.8b 3 Global market predicted to grow most common to $14.4b by 2034 cause cancer death 3% 5 year survival rate for advanced disease
Slide 4: Narmafotinib makes other drugs work better
04 05 03 NARMAFOTINIB Makes other drugs work better
Slide 5: ACCENT Pancreatic Cancer Trial
04 ACCENT Pancreatic Cancer Trial Improving treatment outcomes for metastatic pancreatic cancer Narmafotinib Chemotherapy New diagnosed patients Metastatic disease Narmafotinib on top of conventional chemotherapy dose & schedule Taken orally in Australia and South Korea Three infusions days precedin
Slide 6: ACCENT Pancreatic Cancer Trial: Response Rate
05 ACCENT Pancreatic Cancer Trial Excellent response rate - superior to chemotherapy alone Complete Response Rate - 7.8% Disease Control Rate - 70% 80 PART A PART B 1 CR 4 CR 60 % Response 1 Complete Response 4 Complete Responses 40 2 Partial Responses 16 Partial Responses 14 Patients (incl. 1 pCR)
Slide 7: ACCENT Pancreatic Cancer Trial: Survival
06 ACCENT Pancreatic Cancer Trial Excellent response rate - superior to chemotherapy alone Progression Free Survival - 7.7 mo Median Overall Survival - 11.1 mo 8 12 10 6 8 Months Months 4 6 4 2 2 0 0 Narmafotinib + Chemo Chemotherapy Narmafotinib + Chemo Chemotherapy
Slide 8: No Additional Safety Burden to Patients
07 No Additional Safety Burden to Patients Adverse Events (Grade 3 or above) Narmafotinib +Gem/Abr Gem/Abr Adverse Event (AE) Grade ≥ 3 (ACCENT; N=55) (MPACT; N=421) Neutropenia 38.2% 38% Safety Anemia 9.1% 13% Minimal additional burden Diarrhea 5.5% 6% to patients over chemotherapy alone Peripheral
Slide 9: A Fibrotic Shield
08 A Fibrotic Shield Narmafotinib breaks down fibrosis surrounding the tumour, and blocks survival and resistance pathways in cancer cells Chemotherapy NARMAFOTINIB Cancer Associated Fibroblasts Narmafotinib acts to reduce Both narmafotinib produce a dense fibrous the fibrous tissue thus and the che
Slide 10: Other Opportunities
09 Other Opportunities Narmafotinib breaks down fibrosis surrounding the tumour, and blocks survival and resistance pathways in cancer cells Pancreatic Cancer Ovarian Cancer Lung Cancer Combinations with Combinations with Combinations with targeted agents - e.g. standard-of-care targeted agents - e.
Slide 11: Key Milestones
10 Key Milestones Upcoming events Ovarian Cancer Phase 2b/3 Trial Commences registrational Licensing Deal Pancreatic Cancer Trial Commences New clinical study commences 2026 2027 2028 2029 ACCENT Trial Data Regional Licensing or Partnering Deal
Slide 12: A Record of Success
11 A Record of Success The team to progress this project Developed drugs that Broad experience from leading have made it to market pharma and biotech companies
Slide 13: Corporate Summary
CORPORATE SUMMARY 12 ASX:ATX | OTCQB:INNMF 12 month share price chart Share price A$0.135 (06-May-2026) Shares on 513.07M issue Market cap A$69.3M (06-May-2026) Cash at hand A$27.85M (31-Mar-2026) Platinum Investment Substantial Management Ltd Shareholders Acorn Capital Ltd Blueflag Holdings Pty Ltd
Slide 14: Thank You
Thank You Chris Burns PhD GAICD FAHMS Rhiannon Jones PhD GAICD CEO and MD COO [email protected] [email protected] Amplia Therapeutics Limited ASX: ATX | OTCQB: INNMF [email protected] ampliatx.com
Amplia Therapeutics — Investor Presentation (May 2026) on 6ix